Compass Pathways Plc

Compass Pathways is the most advanced psychedelic-medicine company in the world. Its lead drug candidate, COMP360, is a proprietary synthetic formulation of psilocybin and — after two successful Phase 3 trials in treatment-resistant depression — is now the first classic psychedelic ever to clear Phase 3 and move into a rolling NDA filing at the FDA.

The company went public on September 18, 2020 at $17.00 per share and ran to an all-time high just under $60.00 in early 2021 on excitement about being the first publicly traded psychedelic-medicine developer. It then ground through a five-year Phase 2b-to-Phase 3 development cycle, multiple dilutive raises, and a depressed biotech tape, printing an all-time low of ~$2.25 in June 2025 around the Trump tariff-driven market selloff. The stock is now trading at approximately $9.30 — quadrupled off the low, but still ~45% below its IPO price and ~84% below its all-time high.

What changed: the science finally cleared the bar, the regulatory environment turned actively supportive, and the balance sheet stopped being a risk. The setup now is rare for clinical-stage biotech — de-risked science, an FDA submission in motion, a supportive White House, an emerging nationwide clinic distribution network, and cash through launch. Wall Street's six covering analysts have a mean target of $24.83 (median $16.50), implying roughly 77% upside on the median and 167% on the mean — with H.C. Wainwright's high target of $70 implying more than a seven-bagger from current levels.

Wall Street is unusually unified on CMPS. Six sell-side firms publish active coverage, all with Buy or Overweight ratings. Targets range from $14 to $70, with a mean of $24.83 and a median of $16.50. From CMPS’s current ~$9.30, that implies roughly 77% upside on the median and 167% upside on the mean. The Street’s high target of $70 (H.C. Wainwright) implies more than a 7x from current levels — though we note H.C. Wainwright is a clear outlier; excluding it, the mean of the other five drops to $15.80.

CMPS is a rare setup: de-risked science, an FDA submission in motion, a supportive White House, an emerging nationwide clinic distribution network, and a balance sheet that no longer needs a dilutive raise before launch. The stock has already quadrupled from the June 2025 all-time low, yet still sits ~45% below its IPO price and ~84% below its all-time high. Wall Street targets imply roughly 77% upside on the median and 167% on the mean, and the Street’s high target ($70, H.C. Wainwright) implies more than a seven-bagger.